Drugs obtained by biotechnology processing by Almeida, Hugo et al.
*Correspondence: H. Almeida, Serviço de Tecnologia Farmacêutica, Faculdade 
de Farmácia, Universidade do Porto, Rua Aníbal Cunha, n.164, 4050-047 – 
Porto, Portugal. E-mail.: hperas5@hotmail.com
R
ev
ie
w
Brazilian Journal of 
Pharmaceutical Sciences
vol. 47, n. 2, apr./jun., 2011
Drugs obtained by biotechnology processing
Hugo Almeida*, Maria Helena Amaral, Paulo Lobão
Pharmaceutical Technology Service, Faculty of Pharmacy, University of Porto, Porto, Portugal
In recent years, the number of drugs of biotechnological origin available for many different diseases has 
increased exponentially, including different types of cancer, diabetes mellitus, infectious diseases (e.g. 
AIDS Virus / HIV) as well as cardiovascular, neurological, respiratory, and autoimmune diseases, among 
others. The pharmaceutical industry has used different technologies to obtain new and promising active 
ingredients, as exemplified by the fermentation technique, recombinant DNA technique and the hybridoma 
technique. The expiry of the patents of the first drugs of biotechnological origin and the consequent 
emergence of biosimilar products, have posed various questions to health authorities worldwide regarding 
the definition, framework, and requirements for authorization to market such products.
Uniterms: Biotechnology. Recombinant DNA. Hybridoma technique. Bacteria. Antibiotics. Vaccines.
Nos últimos anos, tem aumentado exponencialmente o número de fármacos de origem biotecnológica 
ao dispor das mais diversas patologias, entre elas destacam-se, os diferentes tipos de cancêr, as doenças 
infecciosas (ex. vírus AIDS/HIV), as doenças autoimunes, as doenças cardiovasculares, a Diabetes 
Mellitus, as doenças neurológicas, as doenças respiratórias, entre outras. A indústria farmacêutica tem 
recorrido a diferentes tecnologias para a obtenção de novos e promissores princípios ativos, como 
são exemplo a fermentação, a técnica de DNA Recombinante, a técnica de hidridoma, entre outras. A 
queda das patentes dos primeiros fármacos de origem biotecnológica e o consequente aparecimento 
dos produtos biossimilares têm colocado diferentes questões às autoridades de saúde mundiais, sobre 
a definição, enquadramento e exigências para a autorização de entrada no mercado deste tipo de  
produtos.
Unitermos: Biotecnologia. DNA recombinante. Técnica de Hibridoma. Bactérias. Antibióticos. Vacinas.
INTRODUCTION
The word biotechnology was first used by Karl 
Ereky (Hungarian agricultural engineer) in 1919, featuring 
the use of living organisms on a given raw material for 
the purpose of obtaining a particular product and introdu-
cing the concept of genetic change (Fári, Kralovánszky, 
2006). Biotechnology is based on scientific knowledge 
from different disciplines such as Microbiology, Bioche-
mistry, Genetics, Chemistry, Engineering and Computer 
Science for biological agents such as microorganisms, 
cells or molecules (enzymes, antibodies, DNA, etc.) to 
provide goods and ensure services (Bunders et al., 1996). 
This multidisciplinary approach is the most important 
characteristic of this scientific field of study in constant 
evolution.
In recent years, the biotech industry has been remar-
kable since it is associated with high efficiency production 
processes, low manpower, low costs, an environmentally-
friendly industry, with low energy consumption and redu-
ced emission of greenhouse gases (Tang, Zhao, 2009). The 
pharmaceutical industry, in their attempts to discover new 
molecules, has found an ally in the biotechnology industry, 
with exponential growth (Bingham, Ekins, 2009). Thus, 
the biggest global pharmaceutical companies are buying 
companies linked to biotechnological research and produc-
tion (Malik, 2009). The aim of this paper was to review the 
most important biopharmaceuticals, such as blood factors, 
hormones, cytokines, enzymes, vaccines and monoclonal 
antibodies.
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BIOTECHNOLOGY PROCESSES
Current biotechnological processes essentially 
involve five different groups of organisms: bacteria (e.g. 
Escherichia coli, Pseudomonas spp. Serratia mascescens, 
Erwenia herbícola, Lactococcus lactis and Bacillus sub-
tilis), fungi (e.g. Saccharomyces cerevisiae, Pichia and 
Hansenula, Trichoderma and Aspergilli), plants (e.g. to-
bacco plant, rape and transgenic potatoes (Tourte, 1998)), 
insects (e.g. Spodoptra frugiperda) and mammalians (e.g. 
Chinese hamster ovary cells (CHO), baby hamster kid-
ney cells (BHK) and transgenic animals) (Walsh, Gary, 
2003).
The application of different techniques allows chan-
ges to be made in microorganisms, in order to highlight a 
particular feature or increase their production and ultima-
tely the production of new products. For this, conventional 
genetic techniques such as mutagenesis, fermentation, 
sexual and parasexual processes or modern techniques 
such as recombinant DNA techniques or the hybridoma 
technique, can be used (Ferreira, Sousa, 1998).
Examples of drugs obtained by biotechnology 
processes
Biopharmaceutical forms are potent, reactive, unsta-
ble and very expensive (Bruggemeier, 2006; Rader, 2008). 
They have several advantages such as the provision of 
effective treatments in chronic and uncommon diseases. 
Recombinant drugs (Factor VIII for hemophilia), offer sa-
fer and reduced side effects, improve on existing therapies 
and can be produced on a large scale by biotechnological 
processes.
According to the PhRMA (The Pharmaceutical Re-
search and Manufacturers of America), in 2008 some 633 
biotechnological therapeutic products were undergoing 
development for over 100 different diseases, encom-
passing 254 malignancies, 162 for infectious diseases, 
59 for autoimmune diseases, and 34 for the HIV/AIDS 
virus or related diseases (PhRMA, 2008). In 2008, the 
FDA approved 31 new biotechnological drugs and by 
August 2009 a further 12 new biotechnological drugs 
were approved (e.g. intranasal vaccine against seasonal 
influenza virus, treatment in adults of moderate and seve-
re rheumatoid arthritis, prevention of blood coagulation 
in patients with hereditary antithrombin deficiency, etc.) 
(PhRMA, 2009).
These new drugs are now in daily use for the tre-
atment of chronic and rare diseases, for which there was 
hitherto no therapeutic or conventional therapies were 
ineffective.
In the future, biopharmaceuticals may be used 
against the AIDS virus, different types of cancer, asthma, 
Parkinson’s and Alzheimer’s disease. There are different 
groups of biopharmaceuticals, including: antibiotics, 
blood factors, hormones, growth factors, cytokines, en-
zymes, vaccines and monoclonal antibodies.
Antibiotics
Antibiotics are the largest group in terms of econo-
mic importance among the products obtained by fermen-
tation. Some examples of antibiotics whose synthesis 
involved microorganisms include penicillin produced 
from Penicillium notatum; cephalosporins (usually semi-
synthetic process) from the genus Streptomyces; chloram-
phenicol from Streptomyces venezuelae; streptomycin 
from Streptomyces griseus; cycloserine from Streptomyces 
orchidaceus; clindamycin from Streptomyces lincolnensis; 
vancomycin isolated from cultures of Streptomyces orien-
talis (Nocardia orientalis); teicoplanin from Actinmopla-
nes teichomyceticus and mupirocin from Pseudomonas 
fluoresces (Osswald, Guimarães, 2001).
Blood Factors
Even with identical causes, two types of hemophilia 
can be distinguished, namely, hemophilia A (the deficient 
or abnormal element is Factor VIII or antihemophilic 
factor A) and hemophilia B (the deficient or abnormal 
element is Factor IX or antihemophilic Factor B) (Stein-
berg, Raso, 1998a).
These two blood clotting factors are produced by 
recombinant techniques. The recombinant Factor VIII 
produced in CHO cells, containing 1438 a.a. is used in 
the treatment of hemophilia A (a hereditary disease cha-
racterized by slow blood clotting and difficulty controlling 
blood loss) (Bhopale, Nanda, 2005a). Another example is 
the Factor IX produced in CHO cells, containing 415 a.a. 
used in the treatment of hemophilia B (Bhopale, Nanda, 
2005b). The gene that produces this factor was cloned in 
a sheep by a Scottish laboratory in 1997, and this sheep 
TABLE I – Some examples of diseases and respective 
biopharmaceuticals used in treatment
Disease Active substance
Hepatitis C Interferon α
Multiple Sclerosis Interferon β
Renal Cancer Interleukin
Hemophilia Factor VIII and Factor IX
Diabetes Human Insulin
Anemia Erythropoietin
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subsequently produced milk that contained this factor 
(Steinberg, Raso, 1998b).
In 2009, the FDA approved Atryn® (antithrombin 
recombinant), the first medicine produced using geneti-
cally engineered animals. This protein with anticoagulant 
and anti-inflammatory properties is produced in the milk 
of goats that have been genetically modified. Atryn® is 
used for the prevention of peri-operative and peri-partum 
thromboembolic events in hereditary antithrombin defi-
cient patients. The European Medicines Agency (EMEA) 
also announced approval of the first drug produced in 
an animal bioreactor: Atryn from GTC Biotherapeutics 
(EMEA, 2011). 
Hormones
In 1982, the FDA approved the first dosage form 
obtained through biotechnological processes, recombinant 
human insulin for the treatment of patients with diabetes, 
using recombinant DNA techniques in the bacteria E. coli 
(Humulin®, Novolin®, Velosulin®). Today, recombinant 
human insulin is available in different concentrations 
under different forms of therapeutic action (insulin lispro, 
insulin aspart, insulin glargine - respectively, very fast, 
fast, long acting) and for different applications (intra-
muscular, sub-cutaneous, etc.).
The recombinant human growth hormone impro-
ved the long-term treatment of children whose body was 
not producing enough growth hormone. Somatropin is 
a recombinant human growth hormone, marketed under 
different brand names such as Saizen®, Nutropin®, Huma-
trope® and Serostin®.
Growth Factors
Many Hematopoietic Growth Factors (HGFs) have 
been isolated, and the understanding of their clinical 
potential continues to grow. HGFs have had a significant 
impact on the prevention of infections associated with 
chemotherapy-induced neutropenia, chemotherapy-
induced thrombocytopenia, and chemotherapy-induced 
anemia. Patients with HIV/AIDS can also been helped by 
the administration of recombinant HGFs (Foote, 2008).
Erythropoietin, a hormone produced by the kidneys, 
stimulates the bone marrow to produce red blood cells. The 
recombinant human erythropoietin (Procrit®, Epogen®, 
Eprex®, NeoRecormon®) may appear in different forms: 
alpha (produced in CHO), beta (produced in CHO) and 
gamma (produced in BHK). This recombinant growth fac-
tor is used in the treatment of anemia associated with renal 
failure, HIV infections, surgery, etc. Erythropoietin alpha 
is targeted for the treatment of anemia due to chronic renal 
failure, HIV infection and cancer (Bhopale, Nanda, 2005c).
Another example is Mircera® (beta methoxypolye-
thyleneglycol-epoetin) used for the treatment of anemia 
associated with chronic renal failure (Fajardo et al., 2010). 
On the other hand, Palifermin (Kepivance®) is very similar 
to a natural growth factor that exists in the human body, 
known as keratinocyte growth factor (KGF). Kepivance® 
stimulates the growth of cells, helping to reduce the inci-
dence, severity and duration of oral mucositis in cancer 
patients subjected to intensive care (Hille et al., 2010).
Cytokines
Cytokines are molecules that activate the immune 
cells (e.g. lymphocytes and macrophages), regulate growth 
and differentiation of immune cells, also important mes-
sengers in cells, influencing the response in inflammation, 
response immune and tissue repair (Mahmoud, 2007).
Interleukins are molecules that act as leukocytes 
messengers, for example the interleukin-2 stimulates T 
lymphocytes. IL-2 recombinant interleukin, approved by 
FDA, produced by E. coli, which differs from the natural 
interleukin by the alanine absence on the N-terminal and 
by the fact that serine is replaced by cysteine at 125 ami-
no acid 125, as exemplified in aldesleukin (Proleucina®). 
This drug is used in the treatment of renal cell cancer, and 
its effect is proportional to the amount of recombinant 
drug administered (Bhopale, Nanda, 2005d). There are 
other drugs that block interleukin, for example, Arcalyst® 
(rilonacept) used for the treatment of CAPS - Cryopyrin 
Associated Periodic Syndromes. This drug blocks a chemi-
cal messenger called interleukin-1-beta and interleukin-
1-alpha.
The recombinant interferons (potent cytokines that 
act against viruses and against uncontrolled proliferation 
of cells) exist in three forms: alpha, beta and gamma, and 
feature a wide variety of applications. The α recombinant 
interferon is used in patients with Kaposi’s sarcoma, hepa-
titis B, hepatitis C and renal cell cancer. The β recombinant 
interferon (produced by E. coli containing 165 a.a.) is used 
in patients with secondary progressive sclerosis, because 
it inhibits the production of Th1 cytokines and activates 
the monocytes involved in the immune response (Mc-
Coy et al., 2006). Examples of α recombinant interferons 
are Intron-A®, Roferon-A® and Actimmume® whereas 
β recombinant interferons include Avonex®, Rebif® and 
Betaseron®. Finally, γ recombinant interferon (produced 
by E. coli containing 139 a.a.) is used in patients with 
infections associated with chronic granulomatous disease 
(Nasihi, 2000). 
Enzymes
Recombinant dornase alpha (formulated in the form 
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of an aerosol - Pulmozyme®) is an enzyme produced by 
CHO cells, used in the treatment of patients with cystic 
fibrosis, a genetic disorder marked by excessive mucous 
secretions and frequent lung infections (Bryson, Sorkin, 
1994).
Another example of a recombinant enzyme is a plas-
minogen activator, known as alteplase (Activase®), used 
to dissolve blood clots formed in the circulatory system, 
which can cause heart attacks, pulmonary embolisms and 
strokes (Steinberg, Raso, 1998c). On the other hand, Na-
glazyme® (Galsulfase) is a form of recombinant enzyme 
used for the treatment of patients with mucopolysaccha-
ridosis VI (MPS VI or Maroteaux-Lamy). This disease is 
caused by the lack of an enzyme called B arylsulfatase, 
required in the degradation of substances, known as glyco-
saminoglycans (GAGs). If the enzyme is not present, the 
GAG cannot be degraded and accumulates in cells, causing 
large head and movement difficulties.
Elaprase® (idursulfase) is another enzyme produced 
by biotechnological processes used in the treatment of 
patients with Hunter syndrome (patients are not able to de-
grade glycosaminoglycans, which gradually accumulates 
in cells, affecting most organs, causing difficulty breathing 
and walking) (Okuyama et al., 2010).
Another case of using biotechnology to produce 
drugs is the production of essential enzymes in patients 
with Gaucher syndrome type 1 and 3 (a disease charac-
terized by deficiency of the beta-glucosidase enzyme) 
(Kotulak, 1998). This disease is usually characterized by 
a neurological disorder that includes mental degenera-
tion and seizures. There are a few effective therapies for 
treatment including VPRIV® (velaglucerase alpha - a hu-
man cell line derived enzyme replacement therapy - for 
the long-term treatment of type 1 Gaucher disease), the 
Protalix Biotherapeutics (taliglucerase alpha - a plant 
cell-expressed recombinant glucocerebrosidase enzyme), 
Cerezyme® (imiglucerase - produced by recombinant DNA 
technology using mammalian cell culture, CHO) and Za-
vesca® (miglustat -reduces the harmful build up of fatty 
substances throughout the body by reducing the amount 
of glycosphingolipids produced by the body - used in 
patients who cannot be treated with enzyme replacement 
therapy) (NGF, 2011).
A different enzyme produced using human cell lines 
is alfagalsidase (Replagal®). This enzyme is a copy of the 
human enzyme used in enzyme replacement therapy for 
Fabry’s disease (chronic and progressive genetic diseases 
caused by absence or deficiency of an enzyme called 
alpha-galactosidase A, responsible for the decomposition 
of lipids in the body, consequently the lipids accumulate in 
vital organs causing serious problems) (Ries et al., 2006).
Vaccines
Currently, vaccines are not only developed against 
infectious diseases, but also against drug abuse (nicotine, 
cocaine) and against allergies, cancer and Alzheimer’s 
disease. Despite the success of conventional vaccines, 
there are still many infectious diseases and other chronic 
diseases against which no effective vaccine exists. In 
addition, the growing resistance to the existing arsenal of 
antibiotics increases the need to develop vaccines against 
common bacterial infections. It is expected that novel 
vaccines against several diseases will become available, 
and in these case recombinant technologies hold great 
promise (Jiskoot et al., 2008).
Although conventionally produced vaccines are 
generally harmless, some of them may, rarely, contain 
infectious contaminants. Vaccines whose active ingre-
dients are recombinant antigens do not carry this slight 
risk (Steinberg, 1998a).
Vaccines produced by recombinant DNA techni-
ques have been used to combat seasonal influenza virus 
(Fluarix®, Istivac®, Fluzone®, FluMist®, Agriflu® etc.) and 
hepatitis A and B. The first vaccine against hepatitis B was 
made from plasma derived from patients with chronic 
hepatitis B, and a recombinant vaccine whose sole active 
ingredient is a recombinant antigen has now replaced it 
(Steinberg, 1998b).
There are also other types of vaccines produced 
by genetic engineering, using the yeast Saccharomyces 
cerevisiae for the production of HBsAg or by entering 
the HBsAg gene in mammalian cells (Recombivax HB®, 
Engerix B®) (Laurence, 1997). The Ambirix® vaccine is 
another example of a bivalent vaccine used to protect 
against hepatitis A and hepatitis B (diseases affecting the 
liver) in children aged between 1 and 15 years old, who 
have no immunity to these diseases. This vaccine con-
sists of inactivated hepatitis A virus (produced in human 
diploid cells, MRC-5) and surface antigen of hepatitis B 
(produced in Saccharomyces cerevisiae yeast cells by 
recombinant DNA technology). Another example of a 
vaccine used to protect against hepatitis A and B infection 
is Twinrix®, which contains inactivated hepatitis A virus 
and parts of the hepatitis B virus as active substances 
(surface antigens obtained by recombinant DNA techno-
logy) (FDA, 2010).
On the other hand, the Myobloc® vaccine is a botu-
linum toxin type B vaccine for the treatment of cervical 
dystonia, produced by fermentation using the bacterium 
Clostridium botulinum type B (Royal, 2003). Botulinum 
toxin type A (Botox®) is indicated for the treatment of 
cervical dystonia. The Botox Cosmetic® is used in adults 
under 65 years to raise and fix tissue firmness. Another 
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example of a vaccine produced by genetic engineering 
is Dukoral®, used in protection against cholera (an ex-
tremely serious disease caused by V. cholerae, which is 
contracted from contaminated food or water and causes 
severe diarrhea). This vaccine contains small amounts 
of dead cholera bacteria and a part of the cholera toxin 
called “B subunit” (produced by recombinant DNA) 
(Steinberg, 1998c).
The Gardasil® vaccine is produced by yeast that has 
received a gene allowing the production of L1 protein, and 
is used for vaccination against precancerous lesions in the 
genital area (cervix, vulva and vagina), cervical cancer 
and genital warts secondary to infection caused by types 
6, 11, 16 and 18 of the Human Papillomavirus. Further, 
the vaccine Cervarix® (human papillomavirus bivalent 
recombinant vaccine - types 16 and 18) is used for the 
prevention of cervical cancer and cervical intraepithelial 
neoplasia (CIN) grade 1 and 2 (FDA, 2010).
In March 2009, the FDA approved a vaccine called 
Ixiaro® (produced in mammalian cells, “Vero cells”) in 
order to prevent Japanese encephalitis.
For the first time in world history, a pandemic (the 
first pandemic of the XXI century) had a specific vaccine 
produced in record time (Focetria®, Pandemrix®, Celva-
pan®). With this vaccine, the impacts of this pandemic 
were drastically reduced. The production and marketing 
of a safe and effective monovalent vaccine to combat the 
H1N1 virus, in just a few months after it was considered 
a pandemic, was a major milestone for the pharmaceutical 
industry and for global public health.
Another example of a recombinant vaccine is being 
developed against the Ebola virus. This vaccine is very 
important because this virus kills 50 to 90% of those it in-
fects (Hoenen et al., 2006). It is also important to mention 
the international efforts in obtaining combination vaccines 
for diphtheria, tetanus, Haemophilus influenzae type B, 
hepatitis B and polio. One such example is the vaccine 
Infanrix Penta®, used in vaccination of children aged under 
three years, against diphtheria, tetanus, pertussis, hepatitis 
B and poliomyelitis (Eldred et al., 2006). 
In 2010, the vaccine Menveo® was approved for 
active immunization to prevent invasive meningococcal 
disease caused by Neisseria meningitidis (groups A,C,Y 
and W-135). In the same year the vaccine Prevnar13® was 
approved for active immunization to prevent invasive 
meningococcal disease caused by Streptococcus pneu-
moniae (serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 
19F and 23f – use in children aged 6 weeks to 5 years) and 
for prevention of otitis media caused by Streptococcus 
pneumoniae (serotypes 4, 6B, 9V, 14, 18C, 19F and 23F)
(FDA, 2011).
Malaria, cholera, herpes, lupus, rheumatoid arthritis, 
tuberculosis, HIV/AIDS, cancer and gastrointestinal dise-
ases are diseases for which effective vaccines are expected 
to be developed. In 1998, U.S. researchers announced that 
they had genetically engineered potatoes to produce a 
“vaccine” against cholera (Arakawa et al., 1998). We can 
also highlight other vaccines that are on the horizon such 
as varicella, otitis and acute chronic infectious respiratory 
diseases such as pneumonia caused by Streptococcus 
pneumoniae, Haemophilus influenzae type B, parainfluen-
za virus, rotavirus, Shigella, Vibrio cholerae and certain 
types of Escherichia coli (Marques, 1996).
Monoclonal antibodies
Monoclonal antibodies provide targeted immuno-
suppression that, when used in conjunction with specific 
maintenance immunosuppressants, may allow more speci-
fic therapy and can be used not only for tumor therapy but 
also in other therapies or diagnoses. In recent years, this 
group of drugs has undergone more extensive research, 
and shown a very promising future, as evidenced by the 
amount of drugs that are already on the market.
Table II lists examples of monoclonal antibodies 
on the market for the treatment of different pathologies 
(FDA, 2010).
Expired patents
Another problem that arises today is the expiry of 
the first patent medicines produced by biotechnology pro-
cesses (examples: Intron A®, Humulin®, Serostim® etc.). 
The expiry of these biopharmaceutical patents has given 
rise to a new generation of molecules called biosimilar 
products (Rosset, 2007). European legislation provides 
for the Directive 2004/27/EC of April 2004 that similar 
products are distinguished from generic low molecular 
weight and should be considered on a case by case basis 
(Ronco, 2005). Biosimilar products are more complex and 
less stable than the generic low molecular weight, and the 
efficacy and safety can only be considered based on the 
pre-clinical and clinical trials, including post-marketing 
data/pharmacovigilance (Mellstedt, 2007).
Therefore, the “Committee for Human Medical Pro-
ducts” of the EMEA developed and published, in 2005 and 
2006, specific guidelines for this class of products cove-
ring global guidelines, guidelines for quality, non-clinical 
and clinical trials and specific guidelines for specific pro-
duct classes, necessary to demonstrate that the biosimilar 
products are safe and effective. The first biosimilar drug 
approved by the FDA was Omnitrope (recombinant human 
growth hormone).
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TABLE II – Examples of monoclonal antibodies on the market and their therapeutic indications
Medicine Active Substances Therapeutic Indications Mechanism
Leukoscan® Sulesomab Imaging of bone infection or inflammation Antigranulocyte scintigraphy
Verluma® Nofetumomab Detection Kit for Lung Cancer Directed against a 40-kilodalton (Kd) glycoprotein 
antigen expressed on the surface of numerous tumors
ProstaScint® Capromab Pendetide Diagnosis of prostate cancer Recognizes a prostate specific membrane 
glycoprotein that is chiefly expressed by prostatic 
epithelial cells, (PSMA) 
Rituxan® Rituximab Β cells Non-Hodgkin lymphoma Chimeric monoclonal antibody against the protein 
CD20 found on the surface of B cells
 
Mabthera® Rituximab Follicular lymphoma, diffuse non-Hodgkin 
lymphoma
Chimeric monoclonal antibody against the protein 
CD20 found on the surface of B cells
Simulect® Basiliximab Reduces the incidence and severity of acute 
rejection in kidney transplantation
Blocks the receptor for IL-2, a protein that simulates 
proliferation of T-lymphocytes, which play a key 
role in organ transplant rejection
Remicade® Infliximab Rheumatoid arthritis, Crohn’s disease, 
ankylosing spondylitis, psoriasis
Blocks the effects of tumor necrosis factor alpha 
(TNF-alpha)
Synagis® Palivizumab Against the Human respiratory syncytial virus 
(RSV)
Targets the fusion protein of RSV, inhibiting its entry 
into the cell thereby preventing infection
Zenapax® Daclizumab Reduces the incidence and severity of acute 
rejection in kidney transplantation
Binds specifically to the alpha subunit (p55 alpha, 
CD25, or Tac subunit) of the human high-affinity 
interleukin-2 (IL-2) receptor that is expressed on the 
surface of activated lymphocytes
Herceptin® Trastuzumab Breast Cancer Attaches itself to the HER2 receptors on the surface 
of breast cancer cells blocking them
MabCampath® Alemtuzumab Chronic Lymphocytic Leukemia Locks on to a protein called CD52 (lymphocytes)
Humira® Adalimumab Active rheumatoid arthritis moderate to 
severe, psoriatic arthritis in adults,  
severe active Crohn’s disease
TNF inhibitor
Trudexa® Adalimumab Rheumatoid arthritis TNF inhibitor
ReoPro® Abciximab Antithrombotic Inhibits platelet aggregation
Erbitux® Cetuximab Metastatic colorectal cancer Binds specifically to the extracellular domain of the 
human epidermal growth factor receptor (EGFR).
Raptiva® Efalizumab Chronic and severe plaque psoriasis Binds to human CD11a
Zevalin® Ibritumomab tiuxetan Non-Hodgkin lymphoma CD20-directed radiotherapeutic antibody
Avastin® Bevacizumab Advanced cancer of the colon, breast and lung Recognizes and blocks vascular endothelial growth 
factor A (VEGF-A)
Xolair® Omalizumab First humanized therapeutic antibody for the 
treatment of asthma and the first approved 
therapy designed to target the antibody IgE
Blocks immunoglobulin E (IgE)
Tysabri® Natalizumab Multiple sclerosis in adults Binds to the cell surface receptors known as alpha-4-
beta-1 (VLA-4) and alpha-4-beta-7
Vectibix® Panitumumab Metastatic colorectal cancer that has 
progressed after treatment with other 
chemotherapy
Specific to the epidermal growth factor receptor 
(also known as EGF receptor, EGFR, ErbB-1 and 
HER1 in humans)
Lucentis® Ranibizumab Wet age-related macular degeneration 
(AMD)
Binds to and inhibits all subtypes of vascular 
endothelial growth factor A (VEGF-A)
Drugs obtained by biotechnology processing 205
CONCLUSIONS
Based on biotechnological processes, new subs-
tances with different therapeutic applications, with a 
central focus on quality of life and public health, have 
been developed and produced on a large scale. The 
application of these techniques covers a wide range of 
drug classes such as antibiotics, blood factors, hormo-
nes, hematopoietic growth factors cytokines, enzymes, 
vaccines and monoclonal antibodies.
Although the benefits of using biotechnology are 
clearly evident, a number of concerns and criticisms re-
main regarding the use of some techniques and procedures, 
albeit ethical, including the creation of complete copies 
of living beings (cloning), or environmental, especially in 
the production of varieties of genetically modified living 
organisms, whose impact on natural ecosystems may never 
be determined (Goldstein, Thomas, 2004).
The expiry of the first patent medicines obtained 
by biotechnological processes has given rise to biosimi-
lar products. Specific guidelines for the approval of the-
se products have been defined by regulatory authorities.
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